FENNEC PHARMACEUTICALS INC.FENCEarnings & Financial Report
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Revenue
$7.3M
Gross Profit
N/A
Operating Profit
$-5.0M
Net Profit
$-5.6M
Gross Margin
N/A
Operating Margin
-69.4%
Net Margin
-76.5%
YoY Growth
118.4%
EPS
$-0.20
FENNEC PHARMACEUTICALS INC. Q2 FY2024 Financial Summary
FENNEC PHARMACEUTICALS INC. reported revenue of $7.3M (up 118.4% YoY) for Q2 FY2024, with a net profit of $-5.6M (down 2.0% YoY) (-76.5% margin).
Key Financial Metrics
| Total Revenue | $7.3M |
|---|---|
| Net Profit | $-5.6M |
| Gross Margin | N/A |
| Operating Margin | -69.4% |
| Report Period | Q2 FY2024 |
FENNEC PHARMACEUTICALS INC. Annual Revenue by Year
FENNEC PHARMACEUTICALS INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $44.6M |
| 2024 | $47.5M |
| 2023 | $21.3M |
FENNEC PHARMACEUTICALS INC. Quarterly Revenue & Net Profit History
FENNEC PHARMACEUTICALS INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.8M | +73.8% | $-4.8M | -34.7% |
| Q3 FY2025 | $12.5M | +78.7% | $-638.0K | -5.1% |
| Q2 FY2025 | $9.7M | +32.9% | $-3.2M | -32.7% |
| Q1 FY2025 | $8.8M | -65.5% | $-1.2M | -13.3% |
| Q4 FY2024 | $7.9M | -18.6% | $-2.0M | -25.0% |
| Q3 FY2024 | $7.0M | +7.0% | $-5.7M | -82.2% |
| Q2 FY2024 | $7.3M | +118.4% | $-5.6M | -76.5% |
| Q1 FY2024 | $25.4M | +1413.2% | $12.8M | 50.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.4M | $7.3M | $7.0M | $7.9M | $8.8M | $9.7M | $12.5M | $13.8M |
| YoY Growth | 1413.2% | 118.4% | 7.0% | -18.6% | -65.5% | 32.9% | 78.7% | 73.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $69.2M | $63.2M | $58.9M | $44.9M | $46.4M | $44.9M | $49.3M | $70.6M |
| Liabilities | $66.2M | $64.5M | $64.1M | $50.8M | $52.3M | $52.3M | $53.8M | $35.1M |
| Equity | $3.0M | $-1.4M | $-5.2M | $-5.9M | $-5.9M | $-7.5M | $-4.5M | $35.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $39.0M | $-8.4M | $-2.2M | $-1.5M | $-4.3M | $-3.7M | $1.5M | $-6.0M |